Research & Literature

Managing Prolactinomas during Pregnancy.

Almalki MH, Alzahrani S, Alshahrani F, et al.

Frontiers in endocrinology 2015; (6()):85 doi:10.3389/fendo.2015.00085.

Medical management of functioning pituitary adenoma: an update.

Oki Y

Neurologia medico-chirurgica 2014; (54 Suppl 3()):958-65.

Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.

Wong A, Eloy JA, Couldwell WT, Liu JK

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2015; (22(10)):1562-7.

[Hyperprolactinaemia and bone mineral density].

Kostrzak A, Męczekalski B

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 2015; (39(230)):122-5.

Trigeminal Neuralgia as an Unusual Isolated Symptom of Pituitary Adenoma: Case Report and Review of the Literature.

Gurcan O, Gurcay AG, Kazanci A, et al.

Turkish neurosurgery 2016; (26(1)):180-3 doi:10.5137/1019-5149.JTN.12495-14.1.

[Current diagnosis and treatment of hyperprolactinemia].

Melgar V, Espinosa E, Sosa E, et al.

Revista medica del Instituto Mexicano del Seguro Social 2016; (54(1)):111-21.

Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S

Pituitary 2016; (19(3)):303-10 doi:10.1007/s11102-016-0708-3.

Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.

De Hert M, Detraux J, Stubbs B

Expert opinion on drug safety 2016; (15(6)):809-23 doi:10.1517/14740338.2016.1167873.

Hypopituitarism patterns among adult males with prolactinomas.

Peng J, Qiu M, Qi S, et al.

Clinical neurology and neurosurgery 2016; (144()):112-8.

Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.

Sala E, Bellaviti Buttoni P, Malchiodi E, et al.

Journal of endocrinological investigation 2016; (39(12)):1377-1382 doi:10.1007/s40618-016-0483-z.

A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.

Drake WM, Stiles CE, Bevan JS, et al.

The Journal of clinical endocrinology and metabolism 2016; (101(11)):4189-4194 doi:10.1210/jc.2016-2224.

Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.

Zaidi HA, Cote DJ, Castlen JP, et al.

World neurosurgery 2017; (97()):2-7 doi:10.1016/j.wneu.2016.09.066.

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.

Khare S, Lila AR, Patil R, et al.

Indian journal of endocrinology and metabolism 2017; (21(1)):154-159 doi:10.4103/2230-8210.196010.

Levosulpiride and Serum Prolactin Levels.

Kuchay MS, Mithal A

Indian journal of endocrinology and metabolism 2017; (21(2)):355-358 doi:10.4103/ijem.IJEM_555_16.

'Ectopic' suprasellar type IIa PRL-secreting pituitary adenoma.

Zhou HJ, Pan DS, Ba XQ, et al.

Pituitary 2017; (20(4)):477-484 doi:10.1007/s11102-017-0807-9.

How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.

Karaca Z, Yarman S, Ozbas I, et al.

Journal of endocrinological investigation 2018; (41(1)):129-141 doi:10.1007/s40618-017-0709-8.

Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.

Li BD, Bi ZY, Liu JF, et al.

CNS neuroscience & therapeutics 2017; (23(10)):827-842 doi:10.1111/cns.12727.

Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.

Mohan N, Chia YY, Goh GH, et al.

BMJ case reports 2017; (2017()) doi:10.1136/bcr-2017-220971.

Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.

Hoffmann A, Adelmann S, Lohle K, et al.

European journal of pediatrics 2018; (177(1)):125-132 doi:10.1007/s00431-017-3042-5.

Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Athanasoulia-Kaspar AP, Popp KH, Stalla GK

Endocrine connections 2018; (7(2)):R88-R94 doi:10.1530/EC-18-0030.

Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.

Bernard V, Lamothe S, Beau I, et al.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018; (32(9)):4791-4797 doi:10.1096/fj.201701111RR.

Management of cystic prolactinomas: a review.

Nakhleh A, Shehadeh N, Hochberg I, et al.

Pituitary 2018; (21(4)):425-430 doi:10.1007/s11102-018-0888-0.

Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients.

Lian W, Liu N, Wang RZ, et al.

Clinical and experimental obstetrics & gynecology 2017; (44(2)):203-207.

Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.

Vilar L, Abucham J, Albuquerque JL, et al.

Archives of endocrinology and metabolism 2018; (62(2)):236-263 doi:10.20945/2359-3997000000032.

Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery.

Yi N, Ji L, Zhang Q, et al.

Endocrine 2018; (62(1)):76-82 doi:10.1007/s12020-018-1652-y.

Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq.

Mansour AA, Alhamza AHA, Almomin AMSA, et al.

F1000Research 2018; (7()):430 doi:10.12688/f1000research.13632.2.

A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States.

Cloutier M, Greene M, Touya M, et al.

Journal of medical economics 2018; (21(12)):1183-1190 doi:10.1080/13696998.2018.1521415.

Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases.

Dennison KL, Chack AC, Hickman MP, et al.

PloS one 2018; (13(9)):e0204727 doi:10.1371/journal.pone.0204727.

Management of prolactinoma: a survey of endocrinologists in China.

Ji L, Yi N, Zhang Q, et al.

Endocrine connections 2018; (7(10)):1013-1019.

Giant Prolactinomas.

Shimon I

Neuroendocrinology 2019; (109(1)):51-56 doi:10.1159/000495184.

Management of Dopamine Agonist-Resistant Prolactinoma.

Maiter D

Neuroendocrinology 2019; (109(1)):42-50 doi:10.1159/000495775.

Diagnosis, misdiagnosis and management of hyperprolactinemia.

Healy ML, Smith TPP, McKenna TJ

Expert review of endocrinology & metabolism 2006; (1(1)):123-132 doi:10.1586/17446651.1.1.123.

Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma.

Cain JW, Miljic D, Popovic V, Korbonits M

Expert review of endocrinology & metabolism 2010; (5(5)):681-695 doi:10.1586/eem.10.42.

Untreated Giant Macroprolactinoma with Chronic Cerebrospinal Fluid Leakage: An Unusual Complication.

Mad Naser MN, Aziz NA, Karim NKA

Case reports in endocrinology 2019; (2019()):4825357 doi:10.1155/2019/4825357.

[Differential diagnosis and treatment of pituitary adenomas].

Hlaváč M, Sommer F, Karpel-Massler G, et al.

HNO 2019; (67(4)):307-318 doi:10.1007/s00106-019-0629-3.

Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.

Steeds R, Stiles C, Sharma V, et al.

Clinical endocrinology 2019; (90(5)):662-669 doi:10.1111/cen.13940.

Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.

Steeds RP, Stiles CE, Sharma V, et al.

Echo research and practice 2019; (6(1)):G1-G8.

Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.

Vilar L, Vilar CF, Lyra R, Freitas MDC

Neuroendocrinology 2019; (109(1)):7-19 doi:10.1159/000499694.

First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.

Chiloiro S, Capoluongo ED, Schinzari G, et al.

Frontiers in endocrinology 2019; (10()):365 doi:10.3389/fendo.2019.00365.

The Role of Surgery in the Management of Prolactinomas.

Donoho DA, Laws ER

Neurosurgery clinics of North America 2019; (30(4)):509-514 doi:10.1016/j.nec.2019.05.010.

Magnetic resonance imaging in the management of prolactinomas; a review of the evidence.

Varlamov EV, Hinojosa-Amaya JM, Fleseriu M

Pituitary 2020; (23(1)):16-26 doi:10.1007/s11102-019-01001-6.

Surgery for prolactinomas: a better choice?

Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S

Pituitary 2020; (23(1)):45-51 doi:10.1007/s11102-019-01016-z.

Biochemical diagnosis in prolactinomas: some caveats.

Petersenn S

Pituitary 2020; (23(1)):9-15 doi:10.1007/s11102-019-01024-z.

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA).

Vasilev V, Daly AF, Trivellin G, et al.

Endocrine-related cancer 2020; (27(8)):T77-T86.

Do nothing but observe microprolactinomas: when and how to replace sex hormones?

Bonert V

Pituitary 2020; (23(3)):307-313 doi:10.1007/s11102-020-01039-x.

Predictors of dopamine agonist resistance in prolactinoma patients.

Vermeulen E, D'Haens J, Stadnik T, et al.

BMC endocrine disorders 2020; (20(1)):68 doi:10.1186/s12902-020-0543-4.

Macroprolactinemia Detection by Magnetically Assisted Polyethylene Glycol Precipitation: Potential for Automation.

Smith T, Stern E, Tan E, et al.

The journal of applied laboratory medicine 2020; (5(3)):494-505 doi:10.1093/jalm/jfaa015.

Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center.

Chutpiboonwat P, Yenpinyosuk K, Sridama V, et al.

The Pan African medical journal 2020; (36()):8 doi:10.11604/pamj.2020.36.8.22923.

Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview.

Bilbao Garay I, Daly AF, Egaña Zunzunegi N, Beckers A

Journal of clinical medicine 2020; (9(6)) doi:10.3390/jcm9062003.

The Role of Dopamine Agonists in Pituitary Adenomas.

Giraldi EA, Ioachimescu AG

Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.

Oh JS, Kim HJ, Hann HJ, et al.

Pituitary 2021; (24(1)):38-47 doi:10.1007/s11102-020-01084-6.

The risks of medical treatment of prolactinoma.

Castinetti F, Albarel F, Amodru V, et al.

Annales d'endocrinologie 2021; (82(1)):15-19 doi:10.1016/j.ando.2020.12.008.

Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.

Giese S, Nasi-Kordhishti I, Honegger J

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(3)):163-171 doi:10.1055/a-1247-4908.

Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

Andereggen L, Frey J, Andres RH, et al.

Scientific reports 2021; (11(1)):5122 doi:10.1038/s41598-021-84606-x.

Evaluation of monomeric prolactin level by TRACE method and precipitation with polyethylene glycol.

Vorotnikova SY, Dzeranova LK, Fedorova NS, et al.

Klinicheskaia laboratornaia diagnostika 2021; (66(2)):69-74 doi:10.51620/0869-2084-2021-66-2-69-74.

[Hyperprolactinemia and antipsychotics: it's not always what it seems to be].

Brandsma AE, van der Doelen RHA, Ester WA

Tijdschrift voor psychiatrie 2021; (63(3)):209-214.

Prolactinoma extension as a contributing factor in dopamine agonist-induced CSF rhinorrhea: a systematic review of the literature.

Milton CK, Lee BJ, Voronovich ZA, et al.

British journal of neurosurgery 2023; (37(5)):976-981 doi:10.1080/02688697.2021.1903389.

Drug-induced Hyperprolactinemia Results in Atypical Atypical Fracture.

Lee I, Son DW, Park JH, Park JH

Hip & pelvis 2021; (33(2)):102-107 doi:10.5371/hp.2021.33.2.102.

Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes.

Shariq OA, Lines KE, English KA, et al.

Surgery 2022; (171(1)):77-87 doi:10.1016/j.surg.2021.04.041.

Treatment of hyperprolactinemia: A single-institute experience.

Chen TY, Lee CH, Yang MY, et al.

Journal of the Chinese Medical Association : JCMA 2021; (84(11)):1019-1022 doi:10.1097/JCMA.0000000000000584.

Persistent Idiopathic Prolactin Elevation Merits Macroprolactin Estimation: A Case Report and Review of Literature.

Gautam K, Cherian KE, Jose A, et al.

Journal of human reproductive sciences 2021; (14(2)):206-210 doi:10.4103/jhrs.jhrs_168_20.

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.

Soria-Chacartegui P, Villapalos-García G, Zubiaur P, et al.

Frontiers in pharmacology 2021; (12()):711940 doi:10.3389/fphar.2021.711940.

The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma.

Zandbergen IM, Zamanipoor Najafabadi AH, Pelsma ICM, et al.

Trials 2021; (22(1)):653 doi:10.1186/s13063-021-05604-y.

Early outcomes of endoscopic endonasal approach pituitary adenomas resection with minimal nasal injury.

Tao C, Cheng G, Chen Y, et al.

Medicine 2021; (100(46)):e27843 doi:10.1097/MD.0000000000027843.

Aggressive prolactinoma (Review).

Valea A, Sandru F, Petca A, et al.

Experimental and therapeutic medicine 2022; (23(1)):74 doi:10.3892/etm.2021.10997.

Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia.

Sharma LK, Dutta D, Sharma N, et al.

Journal of laboratory physicians 2021; (13(4)):353-357 doi:10.1055/s-0041-1732490.

Sulpiride-induced hyperprolactinaemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats.

Adán-Castro E, Siqueiros-Márquez L, Ramírez-Hernández G, et al.

Journal of neuroendocrinology 2022; (34(4)):e13091 doi:10.1111/jne.13091.

Update on the clinical management of multiple endocrine neoplasia type 1.

Pieterman CRC, Valk GD

Clinical endocrinology 2022; (97(4)):409-423 doi:10.1111/cen.14727.

The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect.

Faje A, Jones P, Swearingen B, Tritos NA

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(6)):572-577 doi:10.1016/j.eprac.2022.03.013.

Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.

Hamidianjahromi A, Tritos NA

Reviews in endocrine & metabolic disorders 2022; (23(5)):1089-1099 doi:10.1007/s11154-022-09753-6.

Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.

Cho A, Vila G, Marik W, et al.

Frontiers in endocrinology 2022; (13()):901385 doi:10.3389/fendo.2022.901385.

Prolactinoma: Clinical Characteristics, Management and Outcome.

Irfan H, Shafiq W, Siddiqi AI, et al.

Cureus 2022; (14(10)):e29822 doi:10.7759/cureus.29822.

Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review.

Junqueira DR, Bennett D, Huh SY, Casañas I Comabella C

Pharmaceutical medicine 2023; (37(2)):153-166 doi:10.1007/s40290-023-00462-2.

Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.

Rudman Y, Duskin-Bitan H, Richter I, et al.

Andrology 2023; (11(7)):1398-1407 doi:10.1111/andr.13428.

Surgical Management of Giant Prolactinomas: A Descriptive Study.

Lundholm MD, Yogi-Morren D, Pantalone KM, et al.

International journal of endocrinology 2023; (2023()):1990259 doi:10.1155/2023/1990259.

A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature.

Li D, Wang Y, Tan H, et al.

BMC endocrine disorders 2023; (23(1)):107 doi:10.1186/s12902-023-01345-y.

GIANT PROLACTINOMA. A CASE REPORT.

Šulavíková Z, Krásnik V

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti 2023; (79(3)):143-148 doi:10.31348/2023/20.

Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.

Petersenn S, Fleseriu M, Casanueva FF, et al.

Nature reviews. Endocrinology 2023; (19(12)):722-740 doi:10.1038/s41574-023-00886-5.

The Hook Effect: A Case Study of a Giant Invasive Prolactinoma With Falsely Low Serum Prolactin.

Gonçalves RF, Vaz MAS, Rollin G, Rassier Isolan G

Cureus 2023; (15(9)):e46194 doi:10.7759/cureus.46194.

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.

Whyte E, Nezu M, Chik C, Tateno T

Endocrinology and metabolism (Seoul, Korea) 2023; (38(6)):631-654 doi:10.3803/EnM.2023.1838.

Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis.

Nagendra L, Dutta D, Mondal S, et al.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(1)):101453 doi:10.1016/j.jocd.2023.101453.

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas.

Basile M, Valentini I, Attanasio R, et al.

Global & regional health technology assessment 2024; (11()):1-16 doi:10.33393/grhta.2024.2601.

[Overcoming therapy resistance in prolactinomas: from perspectives to real clinical practice].

Shutova AS, Pigarova EA, Lepeshkina LI, et al.

Problemy endokrinologii 2024; (69(6)):63-69 doi:10.14341/probl13351.

Effect of Hyperprolactinemia on Bone Metabolism: Focusing on Osteopenia/Osteoporosis.

Yun SJ, Sang H, Park SY, Chin SO

International journal of molecular sciences 2024; (25(3)) doi:10.3390/ijms25031474.

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri.

Shettima FB, Wakil MA, Sheikh TL, et al.

The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa 2024; (30()):2133 doi:10.4102/sajpsychiatry.v30i0.2133.

Diagnosis of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).

Glezer A, Mendes Garmes H, Kasuki L, et al.

Archives of endocrinology and metabolism 2024; (68()):e230502.

Amitriptyline-Induced Hyperprolactinemia in a Pediatric Patient.

Centner S, Cooper F, Gurnurkar S, Hasan S

Cureus 2024; (16(5)):e59604 doi:10.7759/cureus.59604.

Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

Freda PU

Pituitary 2024; (27(6)):860-873 doi:10.1007/s11102-024-01421-z.

Increase in Testosterone Levels and Improvement of Clinical Symptoms in Eugonadic men With a Prolactin-secreting Adenoma.

Carlier L, Chanson P, Cazabat L, et al.

Journal of the Endocrine Society 2024; (8(9)):bvae135 doi:10.1210/jendso/bvae135.

The Changing Treatment Paradigm for Prolactinoma-A Prospective Series of 100 Consecutive Neurosurgical Cases.

van Trigt VR, Bakker LEH, Pelsma ICM, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(6)):e1833-e1844 doi:10.1210/clinem/dgae652.

THE PLACE OF SURGERY IN THE MANAGEMENT OF PROLACTIN SECRETING ADENOMAS.

Rotariu DI, Costachescu B, Ungureanu MC, et al.

Acta endocrinologica (Bucharest, Romania : 2005) 2024; (20(1)):65-73 doi:10.4183/aeb.2024.65.

Diagnosis and management of pituitary adenomas in children and adolescents.

Maiter D, Chanson P, Constantinescu SM, Linglart A

European journal of endocrinology 2024; (191(4)):R55-R69 doi:10.1093/ejendo/lvae120.

Modern approach to bone comorbidity in prolactinoma.

Uygur MM, Menotti S, Santoro S, Giustina A

Pituitary 2024; (27(6)):802-812 doi:10.1007/s11102-024-01469-x.

Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009-2022.

Mohseni S, Mirdamadi N, Mossavarali S, et al.

Journal of diabetes and metabolic disorders 2024; (23(2)):2143-2149 doi:10.1007/s40200-024-01481-9.

Correlation between MRI findings of pituitary gland and prolactin level among hyperprolactinemia adult female Saudi patients in rural areas: A retrospective multicentric study.

Alyami N, Alhenaki G, Al Atwah S, et al.

Medicine 2025; (104(2)):e40686 doi:10.1097/MD.0000000000040686.

Association of primary hyperparathyroidism with pituitary adenoma and management issues.

Das L, Dutta P

Best practice & research. Clinical endocrinology & metabolism 2025; (39(2)):101978 doi:10.1016/j.beem.2025.101978.

Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.

Detomas M, Altieri B, Nasi-Kordhishti I, et al.

Journal of endocrinological investigation 2025; (48(6)):1363-1370 doi:10.1007/s40618-025-02559-8.

Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population.

Oğuz O, Palaoğlu KE, Incir S

Clinical chemistry and laboratory medicine 2025; (63(9)):1736-1741 doi:10.1515/cclm-2025-0177.

Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy-How Concerned Should We Be?

Daftari G, Tritos NA

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(7)):938-945 doi:10.1016/j.eprac.2025.04.018.

Successful diagnosis and monitoring of giant prolactinomas: the role of sample dilutions.

Schlegel A, Straseski JA

Laboratory medicine 2025; (56(6)):786-789 doi:10.1093/labmed/lmaf021.

Advances in Drug Treatments for Male Patients with Prolactinomas.

Wang DP, Zhou HY, Zhang Y, et al.

Neuroendocrinology 2025; (115(8)):657-677 doi:10.1159/000546443.

High-dose Hook Effect in a Case of Giant Prolactinoma Confounded by Acute Kidney Injury.

Lam A, Prosser C, Chik CL

JCEM case reports 2025; (3(8)):luaf136 doi:10.1210/jcemcr/luaf136.

Clinical, hormonal and radiological features, and treatment outcomes of prolactinomas in a pediatric population.

Emeksiz HC

Northern clinics of Istanbul 2025; (12(3)):269-276 doi:10.14744/nci.2024.65049.

Prolactin impairs erectile function via eNOS suppression independently of testosterone.

Cheng X, Xiao Y, Qiu D, et al.

Toxicology and applied pharmacology 2025; (504()):117532 doi:10.1016/j.taap.2025.117532.

Lipid Profile Differences in Monomeric Hyperprolactinemia, Macroprolactinemia, and Healthy Controls: A Comparative Analysis.

Bahçebaşı S, Gökay F, Şimşek Y

Neuroendocrinology 2025; (115(9)):719-729 doi:10.1159/000547540.

Debate: Surgery as Initial Therapy for Microprolactinoma.

Molitch ME, Mamelak AN

The Journal of clinical endocrinology and metabolism 2025; (110(12)):e4242-e4247 doi:10.1210/clinem/dgaf434.

Management outcomes of prolactinoma: a retrospective study from Southern Iraq.

Alobaidy HF, Alidrisi HA, Reman KA, et al.

Journal of medicine and life 2025; (18(9)):869-877 doi:10.25122/jml-2025-0050.

[Refractory pituitary prolactinoma:current treatment status and challenges].

Zhu HJ

Zhonghua yi xue za zhi 2025; (105(41)):3738-3742 doi:10.3760/cma.j.cn112137-20250824-02165.

[Clinical practice considerations on cabergoline in the treatment of pituitary prolactinoma].

Ye HY, Ji LJ

Zhonghua yi xue za zhi 2025; (105(41)):3743-3746 doi:10.3760/cma.j.cn112137-20250810-02028.

Approach to the Patient With Dopamine-Resistant Microprolactinoma.

Glezer A, Stumpf MAM, Queiroz NL

The Journal of clinical endocrinology and metabolism 2026; (111(3)):879-891 doi:10.1210/clinem/dgaf624.

Giant Prolactinoma: Challenges in Management.

Sharma S, Acharya M, Sherpa C

AACE endocrinology and diabetes 2025; (12(4)):260-264 doi:10.1016/j.aed.2025.07.004.